| CBC . | pt . | r.v. . | Biochemistry . | pt . | r.v. . | Serology . | pt . | r.v. . |
|---|---|---|---|---|---|---|---|---|
| WBC (/mm3) | 4240 | 4000–8000 | TP (g/dl) | 6.3 | 6.6–8.1 | CRP (mg/dl) | 3.55 | 0.00–0.14 |
| Neut. (%) | 61.8 | 40–60 | ALB (g/dl) | 3.1 | 4.1–5.1 | Ferritin (ng/ml) | 254.1 | 30–250 |
| Lymph. (%) | 24.3 | 25–45 | T-Bil (mg/dl) | 1.0 | 0.4–1.5 | CH50 (U/ml) | 42.6 | 30–45 |
| Mono. (%) | 11.6 | 3–7 | AST (U/l) | 11 | 13–30 | IgG (mg/dl) | 1651 | 861–1747 |
| Eosin. (%) | 1.6 | 1–6 | ALT (U/l) | 8 | 10–42 | IgA (mg/dl) | 476 | 93–393 |
| Baso. (%) | 0.7 | 0–1 | AMY (U/l) | 87 | 44–132 | IgM (mg/dl) | 41 | 33–183 |
| RBC (× 104/mm3) | 239 | 430–550 | ALP (U/l) | 79 | 38–113 | IgG4 | 119 | 11–121 |
| Hb (g/dl) | 8.6 | 12–16 | LD (U/l) | 181 | 124–222 | RF (IU/ml) | 4 | <18 |
| Ht (%) | 26 | 39–52 | CK (U/l) | 19 | 59–248 | anti-CCP Ab (U/ml) | 0.3 | <4.5 |
| MCV | 111 | 86–102 | LDL-cho | 96.7 | 65–163 | ANA (titre) | <40 | <40 |
| MCH | 36 | 28–34 | TG (mg/dl) | 56 | 40–234 | PR3-ANCA (U/ml) | 0.0 | <3.5 |
| MCHC | 32 | 29–35 | UA (mg/dl) | 6.1 | 3.7–7.8 | MPO-ANCA (U/ml) | 1.0 | <3.5 |
| PLT (× 104/mm3) | 19.8 | 15–35 | BUN (mg/dl) | 18.4 | 8–20 | sIL-2R (U/ml) | 606.0 | 184–486 |
| Cr (mg/dl) | 1.01 | 0.65–1.07 | ASO (IU/ml) | 42 | <166 | |||
| ESR (mm/h) | 92 | <20 | Na+ (mmol/l) | 137 | 138–145 | ACE (U/l) | 10.9 | 8.3–21.4 |
| K+ (mmol/l) | 4.1 | 3.6–4.8 | ||||||
| Coagulation | Cl− (mmol/l) | 108 | 101–108 | Pathogen tests | ||||
| PT-INR | 1.34 | Ca+ | 8.5 | 8.8–10.1 | SARS-CoV2-PCR | (-) | (-) | |
| APTT (s) | 42.4 | 24.1–31.7 | IP | 2.8 | 2.7–4.61 | β-d-glucan | < 5.0 | <20.0 |
| D-Dimer (μg/ml) | 0.45 | 0.00–0.49 | BS (mg/dl) | 98 | 73–109 | HBs Ag | 0.00 | <0.05 |
| KL-6 (U/ml) | 161 | <500 | HBs Ab | 0.00 | <10.0 | |||
| Urinalysis | NT-ProBNP (pg/ml) | 1805.5 | <126 | HCV Ab | 0.25 | <1.0 | ||
| Protein | (–) | (–) | Vit B12 (pg/ml) | 530 | 180–914 | HIV Ag/Ab | 0.05 | <1.00 |
| Occult blood | (–) | (–) | Folic acid (ng/ml) | 4.5 | >4.0 | TB-specific IFN-γ | (-) | (-) |
| Fe (μg/ml) | 43 | 40–188 | Blood culture | (-) | (-) | |||
| FOB | (–) | (–) | TIBC (μg/dl) | 211 | 253–365 | Scrub typhus IgG/M | (-) | (-) |
| CBC . | pt . | r.v. . | Biochemistry . | pt . | r.v. . | Serology . | pt . | r.v. . |
|---|---|---|---|---|---|---|---|---|
| WBC (/mm3) | 4240 | 4000–8000 | TP (g/dl) | 6.3 | 6.6–8.1 | CRP (mg/dl) | 3.55 | 0.00–0.14 |
| Neut. (%) | 61.8 | 40–60 | ALB (g/dl) | 3.1 | 4.1–5.1 | Ferritin (ng/ml) | 254.1 | 30–250 |
| Lymph. (%) | 24.3 | 25–45 | T-Bil (mg/dl) | 1.0 | 0.4–1.5 | CH50 (U/ml) | 42.6 | 30–45 |
| Mono. (%) | 11.6 | 3–7 | AST (U/l) | 11 | 13–30 | IgG (mg/dl) | 1651 | 861–1747 |
| Eosin. (%) | 1.6 | 1–6 | ALT (U/l) | 8 | 10–42 | IgA (mg/dl) | 476 | 93–393 |
| Baso. (%) | 0.7 | 0–1 | AMY (U/l) | 87 | 44–132 | IgM (mg/dl) | 41 | 33–183 |
| RBC (× 104/mm3) | 239 | 430–550 | ALP (U/l) | 79 | 38–113 | IgG4 | 119 | 11–121 |
| Hb (g/dl) | 8.6 | 12–16 | LD (U/l) | 181 | 124–222 | RF (IU/ml) | 4 | <18 |
| Ht (%) | 26 | 39–52 | CK (U/l) | 19 | 59–248 | anti-CCP Ab (U/ml) | 0.3 | <4.5 |
| MCV | 111 | 86–102 | LDL-cho | 96.7 | 65–163 | ANA (titre) | <40 | <40 |
| MCH | 36 | 28–34 | TG (mg/dl) | 56 | 40–234 | PR3-ANCA (U/ml) | 0.0 | <3.5 |
| MCHC | 32 | 29–35 | UA (mg/dl) | 6.1 | 3.7–7.8 | MPO-ANCA (U/ml) | 1.0 | <3.5 |
| PLT (× 104/mm3) | 19.8 | 15–35 | BUN (mg/dl) | 18.4 | 8–20 | sIL-2R (U/ml) | 606.0 | 184–486 |
| Cr (mg/dl) | 1.01 | 0.65–1.07 | ASO (IU/ml) | 42 | <166 | |||
| ESR (mm/h) | 92 | <20 | Na+ (mmol/l) | 137 | 138–145 | ACE (U/l) | 10.9 | 8.3–21.4 |
| K+ (mmol/l) | 4.1 | 3.6–4.8 | ||||||
| Coagulation | Cl− (mmol/l) | 108 | 101–108 | Pathogen tests | ||||
| PT-INR | 1.34 | Ca+ | 8.5 | 8.8–10.1 | SARS-CoV2-PCR | (-) | (-) | |
| APTT (s) | 42.4 | 24.1–31.7 | IP | 2.8 | 2.7–4.61 | β-d-glucan | < 5.0 | <20.0 |
| D-Dimer (μg/ml) | 0.45 | 0.00–0.49 | BS (mg/dl) | 98 | 73–109 | HBs Ag | 0.00 | <0.05 |
| KL-6 (U/ml) | 161 | <500 | HBs Ab | 0.00 | <10.0 | |||
| Urinalysis | NT-ProBNP (pg/ml) | 1805.5 | <126 | HCV Ab | 0.25 | <1.0 | ||
| Protein | (–) | (–) | Vit B12 (pg/ml) | 530 | 180–914 | HIV Ag/Ab | 0.05 | <1.00 |
| Occult blood | (–) | (–) | Folic acid (ng/ml) | 4.5 | >4.0 | TB-specific IFN-γ | (-) | (-) |
| Fe (μg/ml) | 43 | 40–188 | Blood culture | (-) | (-) | |||
| FOB | (–) | (–) | TIBC (μg/dl) | 211 | 253–365 | Scrub typhus IgG/M | (-) | (-) |
Abbreviations: pt, patient; r.v., reference value; CBC, complete blood count; WBC, white blood cells; Neut., neutrophils; Lymh, lymphocytes; Mono, monocytes; Eosi., eosinocytes; Baso., basophils; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; PLT, platelets; ESR, erythrocyte sedimentation rate; PT-INR, prothrombin time-international normalizsd ratio; APTT, activated partial thromboplastin time; FOB, faecal-occult-blood test; TP, total protein; ALB, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AMY, amylase; ALP, alkaline phosphatase; LD, lactose dehydrogenase; CK, creatine kinase; LDL-cho, low-density lipoprotein cholesterol; TG, triglyceride; UA, uric acid; BUN, blood urea nitrogen; Cr, creatinine; Na+, sodium ion; K+, potassium ion; Cl−, chloride ion, Ca+, calcium ion; IP, inorganic phosphorus; BS, blood sugar; KL-6, Krebs von den Lungen-6; NT-proBNP, N-terminal probrain natriuretic hormone; Vit, vitamin; TIBC, total iron binding capacity; CH50, 50% haemolytic unit of complement; Ig, immunoglobulin; RF, rheumatoid factor; anti-CCP Ab, anticyclic citrullinated peptides antibodies; ANA, antinuclear antibody; PR-3ANCA, proteinase-3 anti-neutrophil cytoplasmic antibody; MPO-ANCA, myeloperoxidase antineutrophil cytoplasmic antibody; sIL-2R, soluble interleukin-2 receptor; ASO, antistreptolysin O antibody; ACE, angiotensin converting enzyme; SARS-CoV2, severe acute respiratory syndrome coronavirus 2; PCR, polymerase chain reaction; HBs, hepatitis B virus surface; Ag, antigen; Ab, antibody; HCV, hepatitis C virus, HIV, human immunodeficiency virus; TB, tuberculosis; IFN; interferon.
| CBC . | pt . | r.v. . | Biochemistry . | pt . | r.v. . | Serology . | pt . | r.v. . |
|---|---|---|---|---|---|---|---|---|
| WBC (/mm3) | 4240 | 4000–8000 | TP (g/dl) | 6.3 | 6.6–8.1 | CRP (mg/dl) | 3.55 | 0.00–0.14 |
| Neut. (%) | 61.8 | 40–60 | ALB (g/dl) | 3.1 | 4.1–5.1 | Ferritin (ng/ml) | 254.1 | 30–250 |
| Lymph. (%) | 24.3 | 25–45 | T-Bil (mg/dl) | 1.0 | 0.4–1.5 | CH50 (U/ml) | 42.6 | 30–45 |
| Mono. (%) | 11.6 | 3–7 | AST (U/l) | 11 | 13–30 | IgG (mg/dl) | 1651 | 861–1747 |
| Eosin. (%) | 1.6 | 1–6 | ALT (U/l) | 8 | 10–42 | IgA (mg/dl) | 476 | 93–393 |
| Baso. (%) | 0.7 | 0–1 | AMY (U/l) | 87 | 44–132 | IgM (mg/dl) | 41 | 33–183 |
| RBC (× 104/mm3) | 239 | 430–550 | ALP (U/l) | 79 | 38–113 | IgG4 | 119 | 11–121 |
| Hb (g/dl) | 8.6 | 12–16 | LD (U/l) | 181 | 124–222 | RF (IU/ml) | 4 | <18 |
| Ht (%) | 26 | 39–52 | CK (U/l) | 19 | 59–248 | anti-CCP Ab (U/ml) | 0.3 | <4.5 |
| MCV | 111 | 86–102 | LDL-cho | 96.7 | 65–163 | ANA (titre) | <40 | <40 |
| MCH | 36 | 28–34 | TG (mg/dl) | 56 | 40–234 | PR3-ANCA (U/ml) | 0.0 | <3.5 |
| MCHC | 32 | 29–35 | UA (mg/dl) | 6.1 | 3.7–7.8 | MPO-ANCA (U/ml) | 1.0 | <3.5 |
| PLT (× 104/mm3) | 19.8 | 15–35 | BUN (mg/dl) | 18.4 | 8–20 | sIL-2R (U/ml) | 606.0 | 184–486 |
| Cr (mg/dl) | 1.01 | 0.65–1.07 | ASO (IU/ml) | 42 | <166 | |||
| ESR (mm/h) | 92 | <20 | Na+ (mmol/l) | 137 | 138–145 | ACE (U/l) | 10.9 | 8.3–21.4 |
| K+ (mmol/l) | 4.1 | 3.6–4.8 | ||||||
| Coagulation | Cl− (mmol/l) | 108 | 101–108 | Pathogen tests | ||||
| PT-INR | 1.34 | Ca+ | 8.5 | 8.8–10.1 | SARS-CoV2-PCR | (-) | (-) | |
| APTT (s) | 42.4 | 24.1–31.7 | IP | 2.8 | 2.7–4.61 | β-d-glucan | < 5.0 | <20.0 |
| D-Dimer (μg/ml) | 0.45 | 0.00–0.49 | BS (mg/dl) | 98 | 73–109 | HBs Ag | 0.00 | <0.05 |
| KL-6 (U/ml) | 161 | <500 | HBs Ab | 0.00 | <10.0 | |||
| Urinalysis | NT-ProBNP (pg/ml) | 1805.5 | <126 | HCV Ab | 0.25 | <1.0 | ||
| Protein | (–) | (–) | Vit B12 (pg/ml) | 530 | 180–914 | HIV Ag/Ab | 0.05 | <1.00 |
| Occult blood | (–) | (–) | Folic acid (ng/ml) | 4.5 | >4.0 | TB-specific IFN-γ | (-) | (-) |
| Fe (μg/ml) | 43 | 40–188 | Blood culture | (-) | (-) | |||
| FOB | (–) | (–) | TIBC (μg/dl) | 211 | 253–365 | Scrub typhus IgG/M | (-) | (-) |
| CBC . | pt . | r.v. . | Biochemistry . | pt . | r.v. . | Serology . | pt . | r.v. . |
|---|---|---|---|---|---|---|---|---|
| WBC (/mm3) | 4240 | 4000–8000 | TP (g/dl) | 6.3 | 6.6–8.1 | CRP (mg/dl) | 3.55 | 0.00–0.14 |
| Neut. (%) | 61.8 | 40–60 | ALB (g/dl) | 3.1 | 4.1–5.1 | Ferritin (ng/ml) | 254.1 | 30–250 |
| Lymph. (%) | 24.3 | 25–45 | T-Bil (mg/dl) | 1.0 | 0.4–1.5 | CH50 (U/ml) | 42.6 | 30–45 |
| Mono. (%) | 11.6 | 3–7 | AST (U/l) | 11 | 13–30 | IgG (mg/dl) | 1651 | 861–1747 |
| Eosin. (%) | 1.6 | 1–6 | ALT (U/l) | 8 | 10–42 | IgA (mg/dl) | 476 | 93–393 |
| Baso. (%) | 0.7 | 0–1 | AMY (U/l) | 87 | 44–132 | IgM (mg/dl) | 41 | 33–183 |
| RBC (× 104/mm3) | 239 | 430–550 | ALP (U/l) | 79 | 38–113 | IgG4 | 119 | 11–121 |
| Hb (g/dl) | 8.6 | 12–16 | LD (U/l) | 181 | 124–222 | RF (IU/ml) | 4 | <18 |
| Ht (%) | 26 | 39–52 | CK (U/l) | 19 | 59–248 | anti-CCP Ab (U/ml) | 0.3 | <4.5 |
| MCV | 111 | 86–102 | LDL-cho | 96.7 | 65–163 | ANA (titre) | <40 | <40 |
| MCH | 36 | 28–34 | TG (mg/dl) | 56 | 40–234 | PR3-ANCA (U/ml) | 0.0 | <3.5 |
| MCHC | 32 | 29–35 | UA (mg/dl) | 6.1 | 3.7–7.8 | MPO-ANCA (U/ml) | 1.0 | <3.5 |
| PLT (× 104/mm3) | 19.8 | 15–35 | BUN (mg/dl) | 18.4 | 8–20 | sIL-2R (U/ml) | 606.0 | 184–486 |
| Cr (mg/dl) | 1.01 | 0.65–1.07 | ASO (IU/ml) | 42 | <166 | |||
| ESR (mm/h) | 92 | <20 | Na+ (mmol/l) | 137 | 138–145 | ACE (U/l) | 10.9 | 8.3–21.4 |
| K+ (mmol/l) | 4.1 | 3.6–4.8 | ||||||
| Coagulation | Cl− (mmol/l) | 108 | 101–108 | Pathogen tests | ||||
| PT-INR | 1.34 | Ca+ | 8.5 | 8.8–10.1 | SARS-CoV2-PCR | (-) | (-) | |
| APTT (s) | 42.4 | 24.1–31.7 | IP | 2.8 | 2.7–4.61 | β-d-glucan | < 5.0 | <20.0 |
| D-Dimer (μg/ml) | 0.45 | 0.00–0.49 | BS (mg/dl) | 98 | 73–109 | HBs Ag | 0.00 | <0.05 |
| KL-6 (U/ml) | 161 | <500 | HBs Ab | 0.00 | <10.0 | |||
| Urinalysis | NT-ProBNP (pg/ml) | 1805.5 | <126 | HCV Ab | 0.25 | <1.0 | ||
| Protein | (–) | (–) | Vit B12 (pg/ml) | 530 | 180–914 | HIV Ag/Ab | 0.05 | <1.00 |
| Occult blood | (–) | (–) | Folic acid (ng/ml) | 4.5 | >4.0 | TB-specific IFN-γ | (-) | (-) |
| Fe (μg/ml) | 43 | 40–188 | Blood culture | (-) | (-) | |||
| FOB | (–) | (–) | TIBC (μg/dl) | 211 | 253–365 | Scrub typhus IgG/M | (-) | (-) |
Abbreviations: pt, patient; r.v., reference value; CBC, complete blood count; WBC, white blood cells; Neut., neutrophils; Lymh, lymphocytes; Mono, monocytes; Eosi., eosinocytes; Baso., basophils; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; PLT, platelets; ESR, erythrocyte sedimentation rate; PT-INR, prothrombin time-international normalizsd ratio; APTT, activated partial thromboplastin time; FOB, faecal-occult-blood test; TP, total protein; ALB, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AMY, amylase; ALP, alkaline phosphatase; LD, lactose dehydrogenase; CK, creatine kinase; LDL-cho, low-density lipoprotein cholesterol; TG, triglyceride; UA, uric acid; BUN, blood urea nitrogen; Cr, creatinine; Na+, sodium ion; K+, potassium ion; Cl−, chloride ion, Ca+, calcium ion; IP, inorganic phosphorus; BS, blood sugar; KL-6, Krebs von den Lungen-6; NT-proBNP, N-terminal probrain natriuretic hormone; Vit, vitamin; TIBC, total iron binding capacity; CH50, 50% haemolytic unit of complement; Ig, immunoglobulin; RF, rheumatoid factor; anti-CCP Ab, anticyclic citrullinated peptides antibodies; ANA, antinuclear antibody; PR-3ANCA, proteinase-3 anti-neutrophil cytoplasmic antibody; MPO-ANCA, myeloperoxidase antineutrophil cytoplasmic antibody; sIL-2R, soluble interleukin-2 receptor; ASO, antistreptolysin O antibody; ACE, angiotensin converting enzyme; SARS-CoV2, severe acute respiratory syndrome coronavirus 2; PCR, polymerase chain reaction; HBs, hepatitis B virus surface; Ag, antigen; Ab, antibody; HCV, hepatitis C virus, HIV, human immunodeficiency virus; TB, tuberculosis; IFN; interferon.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
